Ann Pharmacol Pharm | Volume 8, Issue 1 | Research Article | Open Access

Indirect Coombs Test and Limitations in RH Incompatibility

Elgun T1* and Kuzey HC2

1Department of Medical Biology, Biruni University, Turkey 2Department of Gynecology and Obstetrics, Memorial Sisli Hospital, Turkey

*Correspondance to: Tuğba Elgün 

Fulltext PDF


Aim: RHD incompatibility occurs in the case of mother is RHD negative (-) when the father and the fetus have RHD positive (+) blood group. Our aim with our study is to determine RH incompatibility reliably and to emphasize the importance of detecting it with non-invasive methods as much as possible. In this way, unnecessary tests and possible risks for RHD(-) fetus will be eliminated. In this study, it is aimed to retrospectively evaluate the accuracy of the Indirect Coombs Test (ICT) and the necessity of RHogam application against the risk of RHD blood group incompatibility that may occur between the mother and the fetus. Material and Methods: Age, weight, gestational week, previous pregnancies, complications, blood group type, ICT results, RHogam administration before and after birth of 40 pregnant women with RHD (-) blood group, who were followed up and delivered in Bruni University Medical Faculty Hospital, between the years 2019-2021 were retrospectively analyzed. Results: In the study, in a sample of 40 people, 30% were RHD (-); The presence of 70% RHD (+) babies was detected. It was the first pregnancy of 17 of the pregnant women. Nine of 40 pregnant women had negative ICT results and 31 had positive. Unnecessary RHogam was implemented to 6 of these pregnant women, although the ICT result was negative. It was observed that the ICT test was negative in the next pregnancy of 17 of 23 pregnant women who had given birth before. This shows that the RH antibody in maternal blood is not at a detectable level.


RH incompatibility; Maternal alloimmunization; RH blood group; Indirect Coombs Test


Elgun T, Kuzey HC. Indirect Coombs Test and Limitations in RH Incompatibility. Ann Pharmacol Pharm. 2023; 8(1): 1208..

Subscribe to Our Newsletter